CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Only Standard TreatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (6)

Name (Synonyms) Correlation
drug297 Centricyte 1000 Wiki 1.00
drug651 IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki 1.00
drug825 Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki 1.00
drug1310 Sterile Normal Saline for Intravenous Use Wiki 1.00
drug744 Liberase Enzyme (Roche) Wiki 1.00
drug505 Favipiravir Wiki 0.30

Correlated MeSH Terms (10)

Name (Synonyms) Correlation
D011649 Pulmonary Alveolar Proteinosis NIH 1.00
D054990 Idiopathic Pulmonary Fibrosis NIH 1.00
D011658 Pulmonary Fibrosis NIH 0.45
D017563 Lung Diseases, Interstitial NIH 0.41
D008171 Lung Diseases, NIH 0.38
D011024 Pneumonia, Viral NIH 0.14
D003141 Communicable Diseases NIH 0.10
D007239 Infection NIH 0.07
D045169 Severe Acute Respiratory Syndrome NIH 0.06
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (4)

Name (Synonyms) Correlation
HP:0006517 Alveolar proteinosis HPO 1.00
HP:0002206 Pulmonary fibrosis HPO 0.58
HP:0006515 Interstitial pneumonitis HPO 0.45
HP:0002088 Abnormal lung morphology HPO 0.41

There is one clinical trial.

Clinical Trials

1 Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh

A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019. The clinical characteristics of COVID-19 include respiratory symptoms, fever, cough, dyspnea, and pneumonia. As of 25 February 2020, at least 77 785 cases and 2666 deaths had been identified across China and in other countries; in particular, 977 and 861 cases were identified in South Korea and Japan, respectively. The outbreak has already caused global alarm. On 30 January 2020, the World Health Organization (WHO) declared that the outbreak of SARS-CoV-2 constituted a Public Health Emergency of International Concern (PHEIC), and issued advice in the form of temporary recommendations under the International Health Regulations (IHR).It has been revealed that SARS-CoV-2 has a genome sequence that is 75%-80% identical to that of SARS-CoV, and has more similarities to several bat coronaviruses. SARS-CoV-2 is the seventh reported human-infecting member of the family Coronaviridae, which also includes SARS-CoV and the Middle East respiratory syndrome (MERS)-CoV. It has been identified as the causative agent of COVID-19. Both the clinical and the epidemiological features of COVID-19 patients demonstrate that SARS-CoV-2 infection can lead to intensive care unit (ICU) admission and high mortality. About 16%-21% of people with the virus in China have become severely ill, with a 2%-3% mortality rate. However, there is no specific treatment against the new virus. Therefore, it is urgently necessary to identify effective antiviral agents to combat the disease and explore the clinical effect of antiviral drugs. One efficient approach to discover effective drugs is to test whether the existing antiviral drugs are effective in treating other related viral infections. Several drugs, such as ribavirin, interferon (IFN), Favipiravir (FPV), and Lopinavir (LPV)/ritonavir (RTV), have been used in patients with SARS or MERS, although the efficacy of some drugs remains controversial. It has recently been demonstrated that, as a prodrug, Favipiravir (half maximal effective concentration (EC50) = 61.88 μmol·L−1, half-maximal cytotoxic concentration (CC50) > 400 μmol·L−1, selectivity index (SI) > 6.46) effectively inhibits the SARS-CoV-2 infection in Vero E6 cells (ATCC-1586). Furthermore, other reports show that FPV is effective in protecting mice against Ebola virus challenge, although its EC50 value in Vero E6 cells was as high as 67 μmol·L−1. Therefore, clinical studies are urgently needed to evaluate the efficacy and safety of this antiviral nucleoside for COVID-19 treatment. After enrollment of the patients (day 1) depending on inclusion and exclusion criteria and laboratory findings confirming the presence of the COVID-19 virus, 25 patients will receive Favipiravir plus standard treatment and the second group of 25 patients will receive standard treatment only. The comparison of the findings of the follow up studies on days 4, 7, and 10 in terms of clinical manifestations, chest X-ray and laboratory findings, such as Real Time Polymerase Chain Reaction (RT-PCR) results for viral presence will determine whether Favipiravir has safety and efficacy against COVID-19 infections. All ethical issues related to this trial including right of the participants to withdraw from the study should be maintained according to of guidelines of International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP).

NCT04402203 COVID-19 Favipiravir (Favipira) Drug: Favipiravir Drug: Only Standard Treatment

Primary Outcomes

Description: Negative by RT-PCR for the virus at 4-10 days after initiation of therapy. However, negative results for the viral presence should be with an interval of at least 24 hours.

Measure: Number of participants negative by RT-PCR for the virus at 4-10 days after initiation of therapy.

Time: at 4 to 10 days of therapy

Description: X-ray findings of lung condition improvement at Day-4, Day-7 and Day-10 of therapy

Measure: Number of participants with lung condition change assessed with X-ray.

Time: at Day-4, Day-7 and Day-10 of therapy

Secondary Outcomes

Description: Clinical recovery indicates reduced duration of fever, cough, relief time auxiliary oxygen therapy or noninvasive mechanical ventilation rate.

Measure: Number of participants with clinical recovery

Time: at Day-4, Day-7 and Day-10 of therapy

Measure: Number of participants with adverse effects of drug.

Time: at Day-4, Day-7 and Day-10 of therapy

Measure: Number of participants requiring ICU admission

Time: at Day-4, Day-7 and Day-10 of therapy

Measure: Number of death

Time: at Day-4, Day-7 and Day-10 of therapy

No related HPO nodes (Using clinical trials)